References 1. Mitsias P, Levine SR. Large cerebral vessel occlusive disease in systemic lupus erythematosus. Neurology. In press. 2. Dungan DD, Jay MS. Stroke in an early adolescent with systemic lupus erythematosus and coexistent antiphospholipid antibodies. Pediatrics. 1992;90:96-99. 3. Tsokos GC, Tsokos M, le Riche NGH, Klippel JH. A clinical and pathological study of cerebrovascular disease...

The generation of autoantibodies and autoimmune diseases such as systemic lupus erythematosus has been associated with the use of certain drugs in humans. Early reports suggested that procainamide and hydralazine were associated with the highest risk of developing lupus, quinidine with a moderate risk and all other drugs were considered low or very low risk. More recently, drug-induced lupus ha...

1 Super M, Gillies SD, Foley S, Sastry K, Schweinle JE, Silverman VJ, et al. Distinct and overlapping functions of allelic forms of human mannose binding protein. Nat Genet 1992;2:50–5. 2 Sumiya M, Super M, Tabona P, Levinsky RJ, Arai T, Turner MW, et al. Molecular basis of opsonic defect in immunodeficient children. Lancet 1991;337:1569–70. 3 Garred P, Larsen F, Madsen HO, Koch C. Mannose-bind...

About 50-80% of patients with lupus suffer from lupus nephritis which is one of major causes of morbidity and mortality. Renal pathologists and nephrologists should evaluate the degree of histological damages to establish therapeutic plans for lupus nephritis. In order to standardize definitions, to emphasize clinically relevant lesions, and to improve interobserver reproducibility, the Interna...

background: severe preeclampsia is a quite well-known entity with high incidence of both maternal and fetal morbidity and mortality. although little is known about its etiology, inherited disorders of hemostasis and antiphospholipid syndrome have been postulated as common causes. the present study was conducted to evaluate the association of these two entities with preeclampsia in a group of ir...

3. Thatayatikom A, White AJ. Rituximab: A promising therapy in systemic lupus erythematosus. Autoimmun Rev. 2006;5:18--24. 4. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520--35. 5. Cohen SB. Targeting the B cell in rheumatoid arthritis. Best Pract Res Clin Rheumatol. 2010;24:553--63. 6. Fatourechi MM, el-...

704–8. 3. Tripodi A, Chantarangkul V, Clerici M, Mannucci PM. Laboratory diagnosis of Lupus Anticoagulants for patients on oral anticoagulant treatment. Thromb Haemost 2002;88:583–6. 4. Jennings I, Greaves M, Mackie IJ, Kitchen S, Woods TAL, Preston FE. Lupus anticoagulant testing: improvements in performance in a UK NEQAS proficiency testing exercise after dissemination of national guidelines ...

Abstract Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multiple organs. Recent studies suggest relevance between cysteine protease cathepsin S (CTSS) expression and SLE. To investigate the mechanism of CTSS in SLE, CTSS-overexpressing transgenic (TG) mice were generated, induced lupus-like symptoms. Eight months later, TG spontaneously developed typical SLE sym...

An acquired loss of renal DNaseI promotes transformation of mild mesangial lupus nephritis into membranoproliferative end-stage organ disease. In this study, we analyzed expression profiles of DNaseI in other organs of lupus-prone (NZB×NZW)F1 mice during disease progression to determine whether silencing of the renal DNaseI gene is an organ-specific feature or whether loss of DNaseI reflects a ...

doi: https://doi.org/10.12669/pjms.39.4.7542
 How to cite this: Liu S, Yu X, Li X. A new promising biological agent for refractory lupus nephritis: Telitacicept. Pak J Med Sci. 2023;39(4):---------. https://doi.org/10.12669/pjms.39.4.7542